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Aim To investigate whether therapeutic serum drug lev-
els may be achieved with a single enteral loading dose of 
phenobarbital.
Methods The study was performed at the Mersin Universi-
ty Hospital in Turkey between April 2004 and August 2006, 
and included 29 newborn babies with seizure. After the 
acute treatment of the seizure with midazolam at a dose of 
0.1 mg/kg, phenobarbital was administered by orogastric 
route at a loading dose of 20 mg/kg. Serum phenobarbital 
concentrations were measured at 0.5, 3, 6, and 12 hours 
after the loading. Serum phenobarbital levels between 10-
30 μg/mL were considered as the therapeutic range.
Results The serum phenobarbital levels reached thera-
peutic values in 9 (31%), 19 (66%), 21 (72%), and 23 (79%) 
patients at 0.5, 3, 6, and 12 hours after loading, respectively, 
while they did not reach therapeutic values in 6 patients 
(21%) after 12 hours. Four of the patients in whom there 
was no increase in serum phenobarbital levels had hypox-
ic-ischemic encephalopathy.
Conclusion Enteral loading of phenobarbital can achieve 
therapeutic serum levels in the large majority of newborn 
babies with seizure and may be safely used in babies with 
the intact gastrointestinal tract.
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Seizures are the most common neurological emergency 
in newborn babies, in whom they occur more frequently 
than in adolescents or adults. The incidence of neonatal 
seizures varies between 0.1% and 8.6% (1-5) and depends 
in part on the gestational age and the nature of the stud-
ied population. The long-term outcome of infants with 
seizures has been associated primarily with the cause of 
seizures, but reports on both laboratory animals and new-
born infants suggest that seizures themselves may have a 
deleterious effect (6-10). Although phenobarbital is com-
monly accepted as the first-choice treatment for seizures 
in newborns, there is no consensus regarding the most 
appropriate treatment (11-13). There is considerable evi-
dence that phenobarbital achieves clinical and electro-
graphic control in one third to one half of babies within a 
few hours, and most physicians choose it to treat neonates 
with seizures (11-15).
Studies evaluating the efficacy of phenobarbital have 
been done using the intravenous form of the drug and all 
therapeutic recommendations have been based on the 
data obtained from these studies. Seizure is usually treated 
with a single intravenous dose of midazolam in the acute 
period, followed by intravenous administration of phe-
nobarbital, and the treatment is continued with intrave-
nous phenytoin. Unfortunately, intravenous formulations 
of phenobarbital are not available in some countries, and 
intravenous phenytoin loading or midazolam infusion is 
usually the first choice of second line antiepileptic drugs. 
In some of these countries, phenobarbital is typically ad-
ministered by enteral loading, but as far we know, no study 
has been published evaluating the efficacy of this method. 
The aim of this study was to investigate whether enterally 
loaded phenobarbital reaches therapeutic serum levels in 
newborn babies with seizure.
MeTHOdS
The study was conducted between April 2004 and Au-
gust 2006 at the Neonatal Intensive Care Unit of Mersin 
University Hospital in Mersin, Turkey. After informed con-
sent had been obtained from one of the parents, 29 ba-
bies with documented clinical or electroencephalographic 
(EEG) seizures were included. Seizures were treated with 
midazolam at a dose of 0.1 mg/kg. If the seizure recurred 
before reaching a therapeutic serum level of phenobarbi-
tal, midazolam therapy was repeated. Following the ini-
tial midazolam treatment of seizure, phenobarbital was 
given by orogastric route at a loading dose of 20 mg/
kg. Serum phenobarbital concentrations were mea-
sured 4 times, at 0.5, 3, 6, and 12 hours after the loading 
dose. The treatment outcome was defined as achieving 
the therapeutic serum levels of phenobarbital. It has been 
suggested that the effective serum concentration range of 
phenobarbital for neonatal seizures is 10-30 μg/mL (16). 
Serum phenobarbital levels were measured by the fluo-
rescence polarization method (Cobas Integra 800, Roche 
Diagnostics, Mannheim, Germany), according to the man-
ufacturer’s instructions.
The occurrence of any electrical or clinical seizure at any 
time after reaching the therapeutic serum level of pheno-
barbital was considered as treatment failure. In this case, 
phenytoin was given intravenously at a loading dose of 20 
mg/kg as the second anticonvulsant drug.
All of the patients were evaluated for any intracranial pa-
thology by cranial ultrasonography, computerized to-
mography, or magnetic resonance imaging techniques. 
Standard electroencephalography was performed on all 
patients soon after loading phenobarbital and then as 
needed. Electrical seizure was defined as an episode last-
ing at least 10 seconds and consisting of a succession of re-
petitive, abnormal electrical discharges with demonstrable 
onset, wave-form morphology, and amplitude (14).
Statistical analyses were performed using SPSS for Win-
dows, version 11.0 (SPSS, Inc., Chicago, IL, USA). The base-
line characteristics of the study population were described 
using frequency and descriptive analysis.
ReSUlTS
A total of 29 patients were enrolled in this study, 18 (62%) 
of whom were male. Their mean gestational age was 
36 ± 3.1 weeks with a mean birth weight of 3033 ± 780 g 
(Table 1). Their primary diagnoses were hypoxic ischemic 
encephalopathy (HIE, 41%), malformations of the central 
nervous system (CNS, 14%), CNS infection (10%), and intra-
cranial hemorrhage (3.4%; Table 1). Abnormal EEG findings 
were present in 55% of patients.
Serum phenobarbital reached therapeutic serum levels in 
9 (31%), 19 (66%), 21 (72%), and 23 (79%) of 29 patients at 
0.5, 3, 6 and 12 hours after the loading dose, respectively 
(Table 2), while they did not reach therapeutic levels in only 
6 patients (21%) at the end of 12 hours, 4 of whom had HIE. 
Serum phenobarbital levels were found to be close to the 
lower limit of the therapeutic range in 2 patients (9.6 and 
9.1 μg/mL).
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Phenobarbital failed to control seizures in 11 (38%) pa-
tients, including the 6 mentioned above who had serum 
phenobarbital levels below the therapeutic margin. The 
mean phenobarbital level (±standard deviation) in 11 pa-
tients was 14.2 ± 7.4 μg/mL and in 5 patients who had se-
rum phenobarbital levels within the therapeutic range it 
was 18.5 ± 5.1 μg/mL. Phenytoin was administered to all 11 
patients as a second drug.
No acute significant side effects potentially resulting from 
the antiepileptic drugs (5) were observed, such as hypo-
tension, arrhythmia, and respiratory depression.
diSCUSSiOn
Our study showed that a single enteral loading dose of 20 
mg/kg phenobarbital achieved therapeutic serum levels 
in the majority of newborn babies with seizure within 12 
hours.
Seizures are the most specific symptom of neonatal neuro-
logic insults. In contrast to seizures in an older child, which 
may be idiopathic or genetic, most neonatal seizures have 
a specific cause (12). The most frequent causes of neona-
tal seizures are HIE, intracranial hemorrhage, and infec-
tions and abnormalities of the central nervous system (1). 
HIE was found to be the most common etiologic factor of 
neonatal seizures in this study. In the majority immature 
infants, electrical seizures are often not accompanied by 
clinical seizure activity. Moreover, certain clinical seizures 
in the newborn consistently fail to appear as EEG seizure 
activity (1). Such seizures include certain subtle seizures, 
most generalized tonic seizures, focal and multifocal clonic 
seizures, and focal and multifocal myoclonic seizures (1). 
In newborns, seizures may have an epileptic origin, even 
in the absence of EEG seizure activity (17). In the present 
study, 55% of clinical seizures in the babies were not con-
sistently accompanied by abnormal EEG. Studies in ani-
mals suggest that seizures themselves are deleterious to 
the development of the immature brain (6-9). Therefore, 
any suspected clinical seizure activity should be treated, 
even if the EEG is normal.
Despite the fact that there are very few controlled studies 
on the medical treatment of neonatal seizures, the usual 
therapeutic approach involves intravenous administra-
tion of benzodiazepine followed by loading and mainte-
nance doses of phenobarbital (3,18). Phenobarbital is still 
the most commonly preferred first-line drug in the long-
term treatment of neonatal seizures (1,11,12,14,15). Since 
intravenous formulations of phenobarbital are not avail-
able in some countries, other intravenous anticonvulsants 
are usually chosen as the first-line drug.
Phenobarbital is reported to control seizures in almost half 
of the affected babies (11,17,19). If phenobarbital fails to 
control the seizure, phenytoin is often recommended as a 
second-line anticonvulsant drug. Babies with seizure may 
fail to respond to both antiepileptic drugs. Orman et al 
(20) has shown that only 33% of neonates responded to 
the initial phenobarbital loading, with 56% responding to 
both phenobarbital and phenytoin. In the study by Painter 
et al (14), complete control of seizures has been achieved 
in only 59% of the neonates using both phenobarbital and 
phenytoin. In the present study, phenobarbital failed to 
control seizures in 38% of the patients. In these cases, phe-
nytoin was used as the second drug.
Phenobarbital is readily and almost completely absorbed 
after oral administration (21). However, in our study intes-
tines may have been affected by hypoxia and absorp-
tion of the drug may have been reduced in babies 
TAble 1. baseline patients’ characteristics*
Characteristic
Gestational age (weeks), mean ± SD 
(min-max)
 36.1 ± 3.0 (29-40)
Birth weight (grams), mean ± SD 
(min-max)
3033 ± 780 (1220-4250)
Postnatal age (days), median (25%-75%)  3 (2-10)
Male, % (n) 62 (18)
Primary cause of seizure, % (n):
HIE 41 (12)
CNS malformations 14 (4)
CNS infection 10 (3)
ICH  3.4 (1)
Other 10 (3)
Undetermined 21 (6)
*Abbreviations: CnS – central nervous system; Hie – hypoxic ischemic 
encephalopathy; iCH – intracranial hemorrhage; Sd – standard devia-
tion.
TAble 2. Patients achieving therapeutic serum levels of pheno-
barbital as a function of time after loading dose
 








0.5 31 (9) 14.19-47.87
3 66 (19) 47.64-82.36
6 72 (21) 55.66-88.34
12 79 (23) 64.18-93.82
*defined as 10-30 μg/ml (16).
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with HIE. In such cases, higher or repeated loading doses 
of phenobarbital may be required to provide therapeutic 
levels of the drug. Lockman et al (22) has reported that the 
lowest effective phenobarbital concentration in their study 
was 16.9 μg/mL. Some authors have observed therapeutic 
benefits at concentrations up to 40-45 μg/mL (23). Since 
the mean phenobarbital level in our study was 15 μg/mL, 
we conclude that higher phenobarbital doses may be more 
effective.
A potential limitation of our study is the relatively small 
number of patients treated with phenobarbital. Other limi-
tations of our study are heterogeneity of patient popula-
tion, the variation in gestational age, and birth weight of 
patients.
In conclusion, an enteral loading dose of 20 mg/kg pheno-
barbital achieved therapeutic serum levels in nearly 80% 
of the newborn babies with clinical or electrical seizure ac-
tivity within 12 hours. Phenobarbital may safely be given 
enterally to achieve adequate serum levels in babies with-
out gastrointestinal problems. Higher or repeated loading 
doses may be required for babies with HIE who may have 
intestinal absorption problems.
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